Table 4.
Hematological analyses in normal rats and type 2 diabetic rats after administration of chromium malate, chromium trichloride and chromium picolinate
| Group | Parameter | ||||||
|---|---|---|---|---|---|---|---|
| WBC (109/L) | LYMPH (109/L)† | MNCC (109/L) | NCC (109/L) | RBC (109/L) | HCT (%) | MCV (fL) | |
| Normal control group | 8.04 ± 1.99 | 8.15 ± 2.11 | 0.85 ± 0.49 | 1.40 ± 0.18 | 8.71 ± 0.10 | 46.76 ± 4.38 | 55.00 ± 1.71 |
| Model group | 13.45 ± 1.93 | 5.87 ± 0.94 | 0.62 ± 0.21 | 2.42 ± 0.26 | 9.61 ± 0.31 | 52.66 ± 1.43 | 57.33 ± 1.75 |
| Chromium trichloride-treated group | 12.41 ± 1.61 | 5.27 ± 1.53a | 0.61 ± 0.20 | 2.07 ± 0.40 | 9.63 ± 0.16 | 52.73 ± 3.69 | 57.25 ± 2.06 |
| Chromium picolinate-treated group | 11.96 ± 1.43 | 6.83 ± 0.95 | 0.66 ± 0.38 | 2.26 ± 0.25 | 9.31 ± 0.92 | 50.50 ± 3.56 | 57.50 ± 1.91 |
| Chromium malate-treated group 1 | 12.72 ± 1.87 | 5.84 ± 0.56 | 0.58 ± 0.18 | 2.20 ± 0.16 | 9.27 ± 0.16 | 52.58 ± 4.97 | 57.50 ± 1.73 |
| Chromium malate-treated group 2 | 13.03 ± 1.07 | 6.20 ± 0.72 | 0.58 ± 0.11 | 2.31 ± 0.31 | 9.32 ± 0.18 | 51.87 ± 1.90 | 57.00 ± 3.00 |
| Chromium malate-treated group 3 | 11.29 ± 4.54 | 6.84 ± 1.92 | 0.65 ± 0.23 | 1.87 ± 0.15 | 8.47 ± 0.39 | 49.35 ± 1.96 | 56.17 ± 1.47 |
| Chromium malate treated group 4 | 10.83 ± 2.30 | 6.72 ± 1.88 | 0.73 ± 0.11 | 1.92 ± 0.34 | 8.35 ± 0.45 | 49.58 ± 2.44 | 56.33 ± 1.97 |
| Chromium malate-treated group 5 | 10.84 ± 2.22 | 6.33 ± 0.58 | 0.78 ± 0.23 | 1.89 ± 0.16 | 8.99 ± 0.02 | 49.70 ± 1.31 | 56.00 ± 2.65 |
| Chromium malate-treated group 6 | 10.62 ± 1.64 | 7.00 ± 1.00 | 0.74 ± 0.22 | 1.89 ± 0.10 | 8.79 ± 0.23 | 49.97 ± 1.14 | 55.50 ± 1.52 |
| Chromium malate-treated group 7 | 10.06 ± 1.69 | 7.95 ± 1.59 | 0.78 ± 0.44 | 1.76 ± 0.55 | 8.74 ± 0.09 | 49.58 ± 3.14 | 55.83 ± 1.72 |
| Chromium malate-treated group 8 | 10.08 ± 1.71 | 7.68 ± 1.48 | 0.75 ± 0.16 | 1.61 ± 0.18 | 8.77 ± 0.65 | 47.80 ± 2.34 | 55.20 ± 1.84 |
| Chromium malate-treated group 9 | 9.40 ± 1.59 | 7.47 ± 1.02 | 0.75 ± 0.12 | 1.59 ± 0.37 | 8.72 ± 0.26 | 47.70 ± 2.55 | 55.50 ± 2.74 |
| Chromium malate control group | 8.07 ± 1.65 | 9.61 ± 2.03 | 0.88 ± 0.26 | 1.19 ± 0.12 | 8.72 ± 0.23 | 46.98 ± 1.97 | 55.20 ± 1.84 |
| Group | Parameter | |||||||
|---|---|---|---|---|---|---|---|---|
| Hb (g/L) | MHbC (Pg) | MCHC (g/L) | PLT (109/L) | PDW (fL) | MPV (fL) | PCT (%) | RDW (fL) | |
| Normal control group | 159.69 ± 16.79 | 17.63 ± 1.15 | 315.60 ± 24.72 | 852.67 ± 37.61 | 13.65 ± 2.45 | 8.43 ± 1.39 | 0.69 ± 0.14 | 14.89 ± 1.05 |
| Model group | 167.50 ± 12.26 | 19.65 ± 1.42 | 336.33 ± 28.15 | 968.33 ± 86.07 | 15.91 ± 1.46 | 10.80 ± 0.74 | 1.33 ± 0.26 | 16.50 ± 1.36 |
| Chromium trichloride-treated group | 165.67 ± 14.04 | 19.05 ± 2.76 | 335.67 ± 24.73 | 964.00 ± 83.72 | 16.30 ± 2.85 | 10.33 ± 0.84 | 1.28 ± 0.27 | 16.73 ± 1.64 |
| Chromium picolinate-treated group | 162.75 ± 12.42 | 19.43 ± 1.42 | 324.00 ± 21.87 | 947.72 ± 95.79 | 15.79 ± 2.34 | 10.05 ± 1.25 | 1.13 ± 0.10 | 16.41 ± 1.04 |
| Chromium malate-treated group 1 | 167.00 ± 15.66 | 19.44 ± 1.39 | 342.00 ± 25.57 | 965.50 ± 29.18 | 15.88 ± 1.59 | 10.64 ± 1.47 | 1.31 ± 0.38 | 16.35 ± 1.67 |
| Chromium malate-treated group 2 | 168.50 ± 12.12 | 19.55 ± 1.21 | 339.00 ± 25.29 | 964.25 ± 71.57 | 15.70 ± 1.85 | 10.60 ± 1.28 | 1.31 ± 0.19 | 16.40 ± 1.70 |
| Chromium malate-treated group 3 | 166.25 ± 14.35 | 19.52 ± 1.34 | 327.33 ± 24.16 | 947.00 ± 51.07 | 15.63 ± 1.33 | 10.37 ± 1.29 | 1.22 ± 0.18 | 16.13 ± 1.72 |
| Chromium malate-treated group 4 | 165.20 ± 13.03 | 19.33 ± 1.57 | 324.67 ± 21.53 | 942.00 ± 41.55 | 15.78 ± 1.10 | 10.28 ± 0.86 | 1.09 ± 0.11 | 16.07 ± 1.70 |
| Chromium malate-treated group 5 | 165.20 ± 13.70 | 18.43 ± 1.37 | 322.14 ± 28.03 | 938.50 ± 28.99 | 14.97 ± 2.68 | 9.67 ± 1.21 | 0.97 ± 0.12 | 15.72 ± 1.42 |
| Chromium malate-treated group 6 | 162.17 ± 16.01 | 18.23 ± 1.67 | 322.50 ± 23.79 | 928.50 ± 30.42 | 14.81 ± 1.01 | 9.43 ± 1.21 | 0.89 ± 0.15 | 15.95 ± 1.07 |
| Chromium malate-treated group 7 | 162.30 ± 16.11 | 18.26 ± 1.07 | 321.70 ± 13.17 | 892.67 ± 56.45 | 14.67 ± 1.47 | 9.09 ± 1.95 | 0.87 ± 0.39 | 15.76 ± 1.85 |
| Chromium malate-treated group 8 | 161.60 ± 13.97 | 18.30 ± 1.17 | 320.75 ± 23.86 | 889.67 ± 61.33 | 14.50 ± 1.71 | 8.87 ± 1.62 | 0.76 ± 0.47 | 15.64 ± 1.39 |
| Chromium malate-treated group 9 | 161.38 ± 13.29 | 18.57 ± 1.06 | 320.00 ± 24.24 | 874.75 ± 33.86 | 14.47 ± 2.67 | 8.73 ± 1.95 | 0.76 ± 0.19 | 15.44 ± 1.29 |
| Chromium malate control group | 158.40 ± 17.12 | 17.47 ± 1.59 | 317.25 ± 24.79 | 795.00 ± 24.68 | 13.73 ± 1.95 | 8.25 ± 1.69 | 0.61 ± 0.15 | 14.49 ± 1.51 |
Data is presented as mean ± standard deviation (n = 10). Chromium trichloride and chromium picolinate were used as positive controls.
Hb, hemoglobin
HCT, hemataocrit
LYMPH, lymphocyte count
MCHC, mean corpuscular hemoglobin concentration
MCV, mean corpuscular volume
MHbC, mean hemoglobin content
MNCC, mononuclear cell count
MPV, platelet mean volume
NCC, neutral cell count
PCT, platelet deposited
PDW, platelet distribution width
PLT, platelet count
RBC, red blood cell
RDW, red cell distribution width
WBC, white blood cell.
†
Significantly different from normal control group (P < 0.05).